Selected Publication:

SHR Neuro Cancer Cardio Lipid Metab Microb

Solomon, SD; McMurray, JJV; Vaduganathan, M; Claggett, B; Jhund, PS; Desai, AS; Henderson, AD; Lam, CSP; Pitt, B; Senni, M; Shah, SJ; Voors, AA; Zannad, F; Abidin, IZ; Alcocer-Gamba, MA; Atherton, JJ; Bauersachs, J; Chang-Sheng, M; Chiang, CE; Chioncel, O; Chopra, V; Comin-Colet, J; Filippatos, G; Fonseca, C; Gajos, G; Goland, S; Goncalvesova, E; Kang, S; Katova, T; Kosiborod, MN; Latkovskis, G; Lee, AP; Linssen, GCM; Llamas-Esperón, G; Mareev, V; Martinez, FA; Melenovský, V; Merkely, B; Nodari, S; Petrie, MC; Saldarriaga, CI; Saraiva, JFK; Sato, N; Schou, M; Sharma, K; Troughton, R; Udell, JA; Ukkonen, H; Vardeny, O; Verma, S; von, Lewinski, D; Voronkov, L; Yilmaz, MB; Zieroth, S; Lay-Flurrie, J; van, Gameren, I; Amarante, F; Kolkhof, P; Viswanathan, P.
Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction.
N Engl J Med. 2024; 391(16):1475-1485 Doi: 10.1056/NEJMoa2407107
Web of Science PubMed FullText FullText_MUG

 

Co-authors Med Uni Graz

von Lewinski Dirk

Altmetrics:

Dimensions Citations:

Plum Analytics:

Scite (citation analytics):

Abstract:

BACKGROUND: Steroidal mineralocorticoid receptor antagonists reduce morbidity and mortality among patients with heart failure and reduced ejection fraction, but their efficacy in those with heart failure and mildly reduced or preserved ejection fraction has not been established. Data regarding the efficacy and safety of the nonsteroidal mineralocorticoid receptor antagonist finerenone in patients with heart failure and mildly reduced or preserved ejection fraction are needed. METHODS: In this international, double-blind trial, we randomly assigned patients with heart failure and a left ventricular ejection fraction of 40% or greater, in a 1:1 ratio, to receive finerenone (at a maximum dose of 20 mg or 40 mg once daily) or matching placebo, in addition to usual therapy. The primary outcome was a composite of total worsening heart failure events (with an event defined as a first or recurrent unplanned hospitalization or urgent visit for heart failure) and death from cardiovascular causes. The components of the primary outcome and safety were also assessed. RESULTS: Over a median follow-up of 32 months, 1083 primary-outcome events occurred in 624 of 3003 patients in the finerenone group, and 1283 primary-outcome events occurred in 719 of 2998 patients in the placebo group (rate ratio, 0.84; 95% confidence interval [CI], 0.74 to 0.95; P = 0.007). The total number of worsening heart failure events was 842 in the finerenone group and 1024 in the placebo group (rate ratio, 0.82; 95% CI, 0.71 to 0.94; P = 0.006). The percentage of patients who died from cardiovascular causes was 8.1% and 8.7%, respectively (hazard ratio, 0.93; 95% CI, 0.78 to 1.11). Finerenone was associated with an increased risk of hyperkalemia and a reduced risk of hypokalemia. CONCLUSIONS: In patients with heart failure and mildly reduced or preserved ejection fraction, finerenone resulted in a significantly lower rate of a composite of total worsening heart failure events and death from cardiovascular causes than placebo. (Funded by Bayer; FINEARTS-HF ClinicalTrials.gov number, NCT04435626.).

Find related publications in this database (using NLM MeSH Indexing)

Aged - administration & dosage

Female - administration & dosage

Humans - administration & dosage

Male - administration & dosage

Middle Aged - administration & dosage

Double-Blind Method - administration & dosage

Follow-Up Studies - administration & dosage

Heart Failure - drug therapy, mortality, physiopathology

Hospitalization - statistics & numerical data

Kaplan-Meier Estimate - administration & dosage

Mineralocorticoid Receptor Antagonists - administration & dosage, adverse effects

Naphthyridines - administration & dosage, adverse effects

Stroke Volume - drug effects, physiology

Aged, 80 and over - administration & dosage

Treatment Outcome - administration & dosage

© Med Uni Graz • Imprint